Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
Sanofi touts promising Ph3 results for its diabetes GLP-1 drug: once-daily lixisenatide
See this week’s Item #6, Sanofi’s Once Daily GLP-1 Lyxumia ® Meets Primary Endpoint in Phase 3 Study.
Sanofi touts promising Ph3 results for its diabetes GLP-1 drug: once-daily lixisenatide
Jun 1, 20111,622 views